ZM 449829

Discontinued Product

1366 has been discontinued.

View all JAK products.
Description: Potent, selective JAK3 inhibitor
Chemical Name: 1-(2-Naphthalenyl)-2-propen-1-one
Purity: ≥98% (HPLC)
Datasheet
Citations (4)
Reviews
Pathways (1)

Biological Activity for ZM 449829

ZM 449829 is a potent, selective inhibitor of Janus tyrosine kinase 3 (JAK3) which binds competitively to the JAK3 ATP site. pIC50 values are 6.8, 5.0, 4.7, and < 5.0 for JAK3, EGFR, JAK1 and CDK4 respectively. Inhibits STAT-5 phosphorylation and T cell proliferation.

Licensing Information

Sold with the permission of AstraZeneca Ltd.

Technical Data for ZM 449829

M. Wt 182.22
Formula C13H10O
Storage Desiccate at -20°C
Purity ≥98% (HPLC)
CAS Number 4452-06-6
PubChem ID 3799
InChI Key FOTCGZPFSUWZBN-UHFFFAOYSA-N
Smiles C=CC(C2=CC1=CC=CC=C1C=C2)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for ZM 449829

Certificate of Analysis / Product Datasheet
Select another batch:

References for ZM 449829

References are publications that support the biological activity of the product.

Brown et al (2000) Naphthyl ketones: a new class of janus kinase 3 inhibitors Bioorg.Med.Chem.Lett. 10 575 PMID: 10741557

Orange et al (2011) IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. J.Clin.Invest. 121 1535 PMID: 21383498

View Related Products by Target

View Related Products by Product Action

View all JAK Inhibitors

Keywords: ZM 449829, ZM 449829 supplier, Potent, selective, JAK3, inhibitors, inhibits, JAK, Kinase, Janus, Activated, Kinases, ZM449829, AstraZeneca, 1366, Tocris Bioscience

4 Citations for ZM 449829

Citations are publications that use Tocris products. Selected citations for ZM 449829 include:

Rogers and Gahring (2015) Upregulation of Nicotinic Acetylcholine Receptor α4+β2 through a Ligand-Independent PI3Kβ Mechanism That Is Enhanced by TNFα and the Jak2/p38Mapk Pathways. PLoS One 10 e0143319 PMID: 26619345

Schaertl et al (2010) A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J Biomol Screen 15 478 PMID: 20395409

Lu et al (2008) JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes. Cell Physiol Biochem 21 305 PMID: 18441519

Gross et al (2006) The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 291 H827 PMID: 16517948


Reviews for ZM 449829

There are currently no reviews for this product. Be the first to review ZM 449829 and earn rewards!

Have you used ZM 449829?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Pathways for ZM 449829

JAK-STAT Signaling Pathway

JAK-STAT Signaling Pathway

The JAK-STAT signaling pathway has several roles, including the control of cell proliferation and hematopoiesis. It is the main signal transduction cascade from cytokine receptors.